Skip to content
10-Q

Quarterly Report

PROTALIX BIOTHERAPEUTICS, INC. PLX

0001104659-26-059756

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 80.57M sh
Shares Diluted Q1 2026 · Mar 31, 2026 83.05M sh
Shares Diluted Q1 2026 · Mar 31, 2025 76.61M sh
Capex Q1 2026 · Mar 31, 2026 $761K
Capex Q1 2026 · Mar 31, 2025 $306K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $22.03M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.06M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $41M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $14.68M
Stockholders Equity Q1 2026 · Mar 31, 2026 $67.23M
Stockholders Equity Q1 2026 · Dec 31, 2025 $48.23M
Stockholders Equity Q1 2026 · Mar 31, 2025 $45.21M
Stockholders Equity Q1 2026 · Dec 31, 2024 $43.21M
Current Liabilities Q1 2026 · Mar 31, 2026 $27.39M
Current Liabilities Q1 2026 · Dec 31, 2025 $26.52M
Total Liabilities Q1 2026 · Mar 31, 2026 $35.11M
Total Liabilities Q1 2026 · Dec 31, 2025 $34.12M
Current Assets Q1 2026 · Mar 31, 2026 $86.36M
Current Assets Q1 2026 · Dec 31, 2025 $66.67M
Total Assets Q1 2026 · Mar 31, 2026 $102.34M
Total Assets Q1 2026 · Dec 31, 2025 $82.35M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.22
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.05
Eps Basic Q1 2026 · Mar 31, 2026 $0.23
Eps Basic Q1 2026 · Mar 31, 2025 −$0.05
Sga Expense Q1 2026 · Mar 31, 2026 $3.05M
Sga Expense Q1 2026 · Mar 31, 2025 $2.6M
Rd Expense Q1 2026 · Mar 31, 2026 $5.43M
Rd Expense Q1 2026 · Mar 31, 2025 $3.48M
Net Income Q1 2026 · Mar 31, 2026 $18.32M
Net Income Q1 2026 · Mar 31, 2025 −$3.62M
Operating Income Q1 2026 · Mar 31, 2026 $21.15M
Operating Income Q1 2026 · Mar 31, 2025 −$4.15M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $4.13M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $8.18M
Revenue Q1 2026 · Mar 31, 2026 $33.75M
Revenue Q1 2026 · Mar 31, 2025 $10.11M